SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: March 9, 2026 to June 24, 2026 DEADLINE: October 5, 2026

According to the Complaint, the Company made false and misleading statements to the market. ARS knew or recklessly disregarded the risk of timeline problems related to CVS Caremark's addition of neffy to its formulary. The Company's guidance on the timeline for insurance coverage for neffy may shift considerably, impacting its commercialization. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about ARS, investors suffered damages.